Abbott Laboratories (ABT) EBT (2009 - 2026)

Abbott Laboratories (ABT) has 18 years of EBT data on file, last reported at $1.4 billion in Q1 2026.

• For the quarter ending Q1 2026, EBT fell 18.5% year-over-year to $1.4 billion; the trailing twelve-month figure through Mar 2026 stood at $8.1 billion (up 10.63% YoY), and the FY2025 full-year result was $8.5 billion, up 20.72% from the prior year.
• EBT eased to $1.4 billion in Q1 2026, from $2.4 billion in the prior quarter.
• In the past five years, EBT ranged from a high of $2.9 billion in Q1 2022 to a low of $1.3 billion in Q4 2022.
• A 5-year average of $1.9 billion and a median of $1.8 billion in 2025 frame the typical range for EBT.
• Across the five-year window, EBT soared 74.48% in 2022 and sank 45.69% in 2023, its largest moves.
• Tracing ABT's EBT over 5 years: stood at $1.3 billion in 2022, then soared by 35.98% to $1.8 billion in 2023, then advanced by 13.09% to $2.0 billion in 2024, then gained by 16.16% to $2.4 billion in 2025, then sank by 38.55% to $1.4 billion in 2026.
• Business Quant data shows ABT's EBT at $1.4 billion in Q1 2026, $2.4 billion in Q4 2025, and $2.2 billion in Q3 2025.